-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Written byWang Cong
EditorWang Duoyu TypesettingShui Chengwen
In October 2021, a company called Neumora Therapeutics announced the completion of a $500 million Series A funding round, and a year later, on October 11, 2022, Neumora announced the completion of a $112 million Series B funding round to advance its precision drug development for the treatment of brain diseases such as neuropsychiatric and neurodegenerative diseases.
While drug development in neuroscience has been known for its high failure rates in recent decades, Neumora is redefining neuroscience research and drug development through a data-driven, precise neurological platform that identifies heterogeneity and subtypes of brain diseases and matches the right patient population to targeted therapies to reduce clinical trial risk, Increase drug development success rates
.
Neumora currently has two drugs in clinical trials, the leading of which is NMRA-140, a kappa opioid antagonist used to treat major depressive disorder
.
NMRA-140 has completed enrollment in a Phase 2a clinical trial (NCT04221230) involving 204 patients with major depressive disorder, an 8-week, double-blind, placebo-controlled clinical trial for the treatment of major depressive disorder
.
Another drug in clinical trials is NMRA-511, an antidiuretic hormone 1a receptor antagonist used to treat anxiety disorders
.
Neumora also plans to conduct a Phase 1 clinical trial of NMRA-266, an M4 muscarinic receptor forward allosteric modulator for the treatment of schizophrenia
, in 2023.
Paul L.
Berns, co-founder, chairman and CEO of Neumora, said that the considerable progress Neumora has made in such a short period of time reflects the urgent need to solve the relative lack of progress and innovation in neuroscience with a data-driven precision medicine approach
.
Paul L.
Berns In addition, Neumora has 4 preclinical development pipelines
for the treatment of neuropsychiatric diseases
such as Parkinson's disease and ALS.
R&D pipeline
Paul L.
Berns said the Series B funding rounds reflect Neumora's continued progress in building a best-in-class neuroscience company, including building a world-class team, expanding industry-leading data science and translational neuroscience platforms, and advancing an extensive and growing pipeline of seven research and development
。
Neumora was incubated by ARCH Venture Partners in 2019, and in October 2021, Neumora completed a $500 million Series A funding round led by ACH, moving out of stealth mode
.
Together with this $112 million Series B financing, its total financing amount exceeds $650 million
.
Neumora relies on a scalable, precision data science platform that leverages multiple open-source and proprietary databases of neuropsychiatric and neurodegenerative diseases collected by Neumora to identify and define patient subtypes
by mapping the mechanisms that drive brain diseases.
Neumora's proprietary neural network technology toolbox integrates multiple types of data from genomics, imaging, EEG, digital, and clinical domains to create the Data Biopsy Signatures™ platform, designed to map underlying disease mechanisms to Precision Phenotypes to identify different patient subtypes™
。 This approach enables companies to match the right patient population with targeted therapies, reducing clinical trial risk and increasing the probability of
improving patient outcomes.
Link: https://neumoratx.
com/about/
open for reprinting Welcome to forward to Moments and WeChat groups
EditorWang Duoyu TypesettingShui Chengwen
In October 2021, a company called Neumora Therapeutics announced the completion of a $500 million Series A funding round, and a year later, on October 11, 2022, Neumora announced the completion of a $112 million Series B funding round to advance its precision drug development for the treatment of brain diseases such as neuropsychiatric and neurodegenerative diseases.
While drug development in neuroscience has been known for its high failure rates in recent decades, Neumora is redefining neuroscience research and drug development through a data-driven, precise neurological platform that identifies heterogeneity and subtypes of brain diseases and matches the right patient population to targeted therapies to reduce clinical trial risk, Increase drug development success rates
.
Neumora currently has two drugs in clinical trials, the leading of which is NMRA-140, a kappa opioid antagonist used to treat major depressive disorder
.
NMRA-140 has completed enrollment in a Phase 2a clinical trial (NCT04221230) involving 204 patients with major depressive disorder, an 8-week, double-blind, placebo-controlled clinical trial for the treatment of major depressive disorder
.
Another drug in clinical trials is NMRA-511, an antidiuretic hormone 1a receptor antagonist used to treat anxiety disorders
.
Neumora also plans to conduct a Phase 1 clinical trial of NMRA-266, an M4 muscarinic receptor forward allosteric modulator for the treatment of schizophrenia
, in 2023.
Paul L.
Berns, co-founder, chairman and CEO of Neumora, said that the considerable progress Neumora has made in such a short period of time reflects the urgent need to solve the relative lack of progress and innovation in neuroscience with a data-driven precision medicine approach
.
Paul L.
Berns In addition, Neumora has 4 preclinical development pipelines
for the treatment of neuropsychiatric diseases
such as Parkinson's disease and ALS.
R&D pipeline
Paul L.
Berns said the Series B funding rounds reflect Neumora's continued progress in building a best-in-class neuroscience company, including building a world-class team, expanding industry-leading data science and translational neuroscience platforms, and advancing an extensive and growing pipeline of seven research and development
。
Neumora was incubated by ARCH Venture Partners in 2019, and in October 2021, Neumora completed a $500 million Series A funding round led by ACH, moving out of stealth mode
.
Together with this $112 million Series B financing, its total financing amount exceeds $650 million
.
Neumora relies on a scalable, precision data science platform that leverages multiple open-source and proprietary databases of neuropsychiatric and neurodegenerative diseases collected by Neumora to identify and define patient subtypes
by mapping the mechanisms that drive brain diseases.
Neumora's proprietary neural network technology toolbox integrates multiple types of data from genomics, imaging, EEG, digital, and clinical domains to create the Data Biopsy Signatures™ platform, designed to map underlying disease mechanisms to Precision Phenotypes to identify different patient subtypes™
。 This approach enables companies to match the right patient population with targeted therapies, reducing clinical trial risk and increasing the probability of
improving patient outcomes.
Link: https://neumoratx.
com/about/
open for reprinting Welcome to forward to Moments and WeChat groups
